Abstract
This session aims to evaluate the efficacy in the reduction of depressive symptoms, and the safety and tolerability of second-generation antipsychotics (SGAs) to manage pediatric bipolar disorder (PBD). CorrectionJournal of the American Academy of Child & Adolescent PsychiatryVol. 61Issue 1PreviewIn the 2021 Scientific Proceedings supplement to JAACAP, New Research Poster 32.1 “Second-Generation Antipsychotics (SGA) in the Management of Acute Pediatric Bipolar Depression: A Systematic Review and Meta-Analysis”, (2021;60:S214), the academic degree of Riddhi Patel, MBBS, MPH, was incorrectly listed, and the name of coauthor Tanya Machado, MBBS, was spelled incorrectly. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
